Wilfried Schgoer

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

Emir Hadzijusufovic, Karin Albrecht-Schgoer, K. Huber et al. · Leukemia · 2017 · 151 citations · Full text

Endothelial Cell Pathobiology, Inflammation, Vasculitis +12

The Angiogenic Factor Secretoneurin Induces Coronary Angiogenesis in a Model of Myocardial Infarction by Stimulation of Vascular Endothelial Growth Factor Signaling in Endothelial Cells

Karin Albrecht-Schgoer, Wilfried Schgoer, Johannes Holfeld et al. · Circulation · 2012 · 110 citations · Full text

The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor–Dependent Mechanism

Markus Theurl, Wilfried Schgoer, Karin Albrecht-Schgoer et al. · Circulation Research · 2010 · 98 citations · Full text

Monocyte migration: A novel effect and signaling pathways of catestatin

Margot Egger, Arno Beer, Markus Theurl et al. · European Journal of Pharmacology · 2008 · 80 citations

Chromatin, Monocyte Migration, Developmental Biology +8